Study of Mana 312 (Multi Tumor-Associated Antigen T Cells) in Adults With AML/MDS After HSCT

Summary

This is a Phase 1, open-label, non-randomized, single and multiple dose escalation study designed to evaluate the safety and preliminary efficacy of administering Mana 312 to subjects with AML/MDS after allogeneic HSCT.

Timeline

Start

2020-12-08

Primary completion

2023-03-28

Completion

2023-03-28

Outcome

Outcome not reported

Stopped: “Product manufacturing”

Drugs

Indications